CoChat
Sign Up
Cited by 492Inflammasome and immune disordersImmune Response and InflammationAutoimmune and Inflammatory Disorders Research

The NLRP3 inflammasome: contributions to inflammation-related diseases

Open access
Chen, Ying, Ye, Xingyan, Escames, Germaine, Lei, Wangrui, Zhang, Xin, Li, Meng, Jing, Tong, Yao, Yu +4 more·2023·Cellular & Molecular Biology Letters
DOI 10.1186/s11658-023-00462-9PMC PMC10303833
Open this paper in CoChat — free accountOpen PDF

Abstract

The NOD-like receptor protein 3 (NLRP3) inflammasome is a protein complex that regulates innate immune responses by activating caspase-1 and the inflammatory cytokines interleukin (IL)-1β and IL-18. Multiple studies have demonstrated the importance of the NLRP3 inflammasome in the development of immune and inflammation-related diseases, including arthritis, Alzheimer’s disease, inflammatory bowel disease, and other autoimmune and autoinflammatory diseases. This review first explains the activation and regulatory mechanism of the NLRP3 inflammasome. Secondly, we focus on the role of the NLRP3 inflammasome in various inflammation-related diseases. Finally, we look forward to new methods for targeting the NLRP3 inflammasome to treat inflammation-related diseases, and provide new ideas for clinical treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s11658-023-00462-9

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IL-1β and IL-18 amplify neuroinflammation and promote pyroptotic cell death.

    “These cytokines amplify neuroinflammation and promote pyroptotic cell death.”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [39]

    The Neurodegenerative diseases section links NLRP3-mediated release of IL-1β and IL-18 to a proinflammatory cycle and describes IL-1β as a proinflammatory factor in Parkinson’s disease. It does not say that these cytokines promote pyroptotic cell death; the Noncanonical activation section instead describes pyroptosis as leading to IL-1β release. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • Oligomeric Aβ is a strong activator of NLRP3 inflammasome in microglia, driving caspase-1 activation and release of IL-1β and IL-18.

    “Oligomeric Aβ is a strong activator of NLRP3, driving caspase-1 activation and subsequent release of pro-inflammatory cytokines IL-1β and IL-18 [39].”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [39]

    The Introduction says aggregated Aβ can activate NLRP3 in microglia, and “Lysosome rupture” describes activation by fibrillar Aβ in an Alzheimer’s mouse model. The “NLRP3 inflammasome” section explains that activation produces mature caspase-1, IL-1β and IL-18. The copy does not specifically identify oligomeric Aβ as a strong activator or directly report both cytokines being released in response to it. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 164

  1. [1]Panda S Nilsson JA Gekara NO Deubiquitinase MYSM1 regulates innate immunity through inactivation of TRAF3 and TRAF6 complexes Immunity 2015 43 4 647 659 10.1016/j.immuni.2015.09.010 26474655 · DOI
  2. [2]Sun R Hedl M Abraham C IL23 induces IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes Gut 2020 69 2 264 273 10.1136/gutjnl-2018-316830 31097538 PMC6858485 · DOI
  3. [4]Chen K Wu T Wang D Li R Shen X Zhao T Transcriptomics and quantitative proteomics reveal changes after second stimulation of bone marrow-derived macrophages from lupus-prone MRL/lpr mice Front Immunol 2022 13 1004232 10.3389/fimmu.2022.1004232 36341359 PMC9627492 · DOI
  4. [5]Ranjan K Hedl M Sinha S Zhang X Abraham C Ubiquitination of ATF6 by disease-associated RNF186 promotes the innate receptor-induced unfolded protein response J Clin Invest 2021 10.1172/JCI145472 34623328 PMC8409591 · DOI
  5. [6]Chou WC Jha S Linhoff MW Ting JP The NLR gene family: from discovery to present day Nat Rev Immunol 2023 10.1038/s41577-023-00849-x 36973360 PMC11171412 · DOI
  6. [7]Higashikuni Y Liu W Numata G Tanaka K Fukuda D Tanaka Y NLRP3 inflammasome activation through heart-brain interaction initiates cardiac inflammation and hypertrophy during pressure overload Circulation 2023 147 4 338 355 10.1161/CIRCULATIONAHA.122.060860 36440584 · DOI
  7. [8]Shahzad K Fatima S Khawaja H Elwakiel A Gadi I Ambreen S Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease Kidney Int 2022 102 4 766 779 10.1016/j.kint.2022.06.010 35779608 · DOI
  8. [9]de Carvalho Ribeiro M Iracheta-Vellve A Babuta M Calenda CD Copeland C Zhuang Y Alcohol-induced extracellular asc specks perpetuate liver inflammation and damage in alcoholic hepatitis even after alcohol cessation Hepatology 2023 10.1097/HEP.0000000000000298 36862512 PMC11921786 · DOI
  9. [10]Ma P Zha S Shen X Zhao Y Li L Yang L NFAT5 mediates hypertonic stress-induced atherosclerosis via activating NLRP3 inflammasome in endothelium Cell Commun Signal 2019 17 1 102 10.1186/s12964-019-0406-7 31429763 PMC6701070 · DOI
  10. [11]VandeWalle L Van Opdenbosch N Jacques P Fossoul A Verheugen E Vogel P Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis Nature 2014 512 7512 69 73 10.1038/nature13322 25043000 PMC4126806 · DOI
  11. [12]Heneka MT McManus RM Latz E Inflammasome signalling in brain function and neurodegenerative disease Nat Rev Neurosci 2018 19 10 610 621 10.1038/s41583-018-0055-7 30206330 · DOI · Paper page
  12. [13]Wang L Fu H Nanayakkara G Li Y Shao Y Johnson C Novel extracellular and nuclear caspase-1 and inflammasomes propagate inflammation and regulate gene expression: a comprehensive database mining study J Hematol Oncol 2016 9 1 122 10.1186/s13045-016-0351-5 27842563 PMC5109738 · DOI
  13. [14]Junqueira C Crespo A Ranjbar S de Lacerda LB Lewandrowski M Ingber J FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation Nature 2022 606 7914 576 584 10.1038/s41586-022-04702-4 35385861 PMC10071495 · DOI
  14. [15]Prochnicki T Vasconcelos MB Robinson KS Mangan MSJ De Graaf D Shkarina K Mitochondrial damage activates the NLRP10 inflammasome Nat Immunol 2023 24 4 595 603 10.1038/s41590-023-01451-y 36941400 · DOI
  15. [17]Zhang Y Yang W Li W Zhao Y NLRP3 inflammasome: checkpoint connecting innate and adaptive immunity in autoimmune diseases Front Immunol 2021 12 732933 10.3389/fimmu.2021.732933 34707607 PMC8542789 · DOI
  16. [18]Xiao L Magupalli VG Wu H Cryo-EM structures of the active NLRP3 inflammasome disc Nature 2023 613 7944 595 600 10.1038/s41586-022-05570-8 36442502 PMC10091861 · DOI
  17. [19]Inoue M Shinohara ML NLRP3 inflammasome and MS/EAE Autoimmune Dis. 2013 2013 859145 23365725 PMC3556409
  18. [20]Lu A Magupalli VG Ruan J Yin Q Atianand MK Vos MR Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes Cell 2014 156 6 1193 1206 10.1016/j.cell.2014.02.008 24630722 PMC4000066 · DOI · Paper page
  19. [21]Brydges SD Broderick L McGeough MD Pena CA Mueller JL Hoffman HM Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies J Clin Invest 2013 123 11 4695 4705 10.1172/JCI71543 24084736 PMC3809806 · DOI
  20. [22]Gurung P Anand PK Malireddi RK VandeWalle L Van Opdenbosch N Dillon CP FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes J Immunol 2014 192 4 1835 1846 10.4049/jimmunol.1302839 24453255 PMC3933570 · DOI
  21. [23]Su H Bidere N Zheng L Cubre A Sakai K Dale J Requirement for caspase-8 in NF-kappaB activation by antigen receptor Science 2005 307 5714 1465 1468 10.1126/science.1104765 15746428 · DOI
  22. [24]Li S Fang Y Zhang Y Song M Zhang X Ding X Microglial NLRP3 inflammasome activates neurotoxic astrocytes in depression-like mice Cell Rep 2022 41 4 111532 10.1016/j.celrep.2022.111532 36288697 · DOI · Paper page
  23. [25]Xu Z Zha X Ji R Zhao H Zhou S Green biosynthesis of silver nanoparticles using aqueous extracts of ageratum conyzoides and their anti-inflammatory effects ACS Appl Mater Interfaces 2023 10.1021/acsami.2c22114 36881383 · DOI
  24. [26]Xie CB Qin L Li G Fang C Kirkiles-Smith NC Tellides G Complement membrane attack complexes assemble NLRP3 inflammasomes triggering IL-1 activation of IFN-gamma-primed human endothelium Circ Res 2019 124 12 1747 1759 10.1161/CIRCRESAHA.119.314845 31170059 PMC6557295 · DOI · Paper page
  25. [27]Ren GM Li J Zhang XC Wang Y Xiao Y Zhang XY Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases Sci Immunol. 2021 10.1126/sciimmunol.abe2933 33931568 · DOI
  26. [28]Spalinger MR Kasper S Gottier C Lang S Atrott K Vavricka SR NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22 J Clin Invest 2016 126 5 1783 1800 10.1172/JCI83669 27043286 PMC4855944 · DOI
  27. [29]Qin Y Li Q Liang W Yan R Tong L Jia M TRIM28 SUMOylates and stabilizes NLRP3 to facilitate inflammasome activation Nat Commun 2021 12 1 4794 10.1038/s41467-021-25033-4 34373456 PMC8352945 · DOI
  28. [30]Ohto U Kamitsukasa Y Ishida H Zhang Z Murakami K Hirama C Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation Proc Natl Acad Sci U S A 2022 119 11 e2121353119 10.1073/pnas.2121353119 35254907 PMC8931350 · DOI
  29. [31]Munoz-Planillo R Kuffa P Martinez-Colon G Smith BL Rajendiran TM Nunez G K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter Immunity 2013 38 6 1142 1153 10.1016/j.immuni.2013.05.016 23809161 PMC3730833 · DOI
  30. [32]Karmakar M Katsnelson MA Dubyak GR Pearlman E Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1beta secretion in response to ATP Nat Commun 2016 7 10555 10.1038/ncomms10555 26877061 PMC4756306 · DOI · Paper page
  31. [33]Piechotta PL Rapedius M Stansfeld PJ Bollepalli MK Ehrlich G Andres-Enguix I The pore structure and gating mechanism of K2P channels EMBO J 2011 30 17 3607 3619 10.1038/emboj.2011.268 21822218 PMC3181484 · DOI
  32. [34]Di A Xiong S Ye Z Malireddi RKS Kometani S Zhong M The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation Immunity 2018 49 1 56 65 e4 10.1016/j.immuni.2018.04.032 29958799 PMC6051907 · DOI
  33. [35]Drinkall S Lawrence CB Ossola B Russell S Bender C Brice NB The two pore potassium channel THIK-1 regulates NLRP3 inflammasome activation Glia 2022 70 7 1301 1316 10.1002/glia.24174 35353387 PMC9314991 · DOI
  34. [36]He Y Zeng MY Yang D Motro B Nunez G NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux Nature 2016 530 7590 354 357 10.1038/nature16959 26814970 PMC4810788 · DOI · Paper page
  35. [37]Sharif H Wang L Wang WL Magupalli VG Andreeva L Qiao Q Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome Nature 2019 570 7761 338 343 10.1038/s41586-019-1295-z 31189953 PMC6774351 · DOI · Paper page
  36. [39]Wu X Gong L Xie L Gu W Wang X Liu Z NLRP3 deficiency protects against intermittent hypoxia-induced neuroinflammation and mitochondrial ROS by promoting the PINK1-Parkin pathway of mitophagy in a murine model of sleep apnea Front Immunol 2021 12 628168 10.3389/fimmu.2021.628168 33717152 PMC7943742 · DOI
  37. [40]Shimada K Crother TR Karlin J Dagvadorj J Chiba N Chen S Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis Immunity 2012 36 3 401 414 10.1016/j.immuni.2012.01.009 22342844 PMC3312986 · DOI · Paper page
  38. [41]Zhong Z Liang S Sanchez-Lopez E He F Shalapour S Lin XJ New mitochondrial DNA synthesis enables NLRP3 inflammasome activation Nature 2018 560 7717 198 203 10.1038/s41586-018-0372-z 30046112 PMC6329306 · DOI · Paper page
  39. [42]Jia X Qiu T Yao X Jiang L Wang N Wei S Arsenic induces hepatic insulin resistance via mtROS-NLRP3 inflammasome pathway J Hazard Mater 2020 399 123034 10.1016/j.jhazmat.2020.123034 32544768 · DOI
  40. [43]Liang H Zhang F Wang W Zhao W Zhou J Feng Y Heat shock transcription factor 2 promotes mitophagy of intestinal epithelial cells through PARL/PINK1/Parkin pathway in ulcerative colitis Front Pharmacol 2022 13 893426 10.3389/fphar.2022.893426 35860016 PMC9289131 · DOI
  41. [45]Pang Y Wu D Ma Y Cao Y Liu Q Tang M Reactive oxygen species trigger NF-kappaB-mediated NLRP3 inflammasome activation involvement in low-dose CdTe QDs exposure-induced hepatotoxicity Redox Biol 2021 47 102157 10.1016/j.redox.2021.102157 34614473 PMC8489155 · DOI
  42. [46]Iyer SS He Q Janczy JR Elliott EI Zhong Z Olivier AK Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation Immunity 2013 39 2 311 323 10.1016/j.immuni.2013.08.001 23954133 PMC3779285 · DOI
  43. [47]Chen J Chen ZJ PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation Nature 2018 564 7734 71 76 10.1038/s41586-018-0761-3 30487600 PMC9402428 · DOI · Paper page
  44. [49]Sheedy FJ Grebe A Rayner KJ Kalantari P Ramkhelawon B Carpenter SB CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation Nat Immunol 2013 14 8 812 820 10.1038/ni.2639 23812099 PMC3720827 · DOI · Paper page
  45. [53]Lerner AG Upton JP Praveen PV Ghosh R Nakagawa Y Igbaria A IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress Cell Metab 2012 16 2 250 264 10.1016/j.cmet.2012.07.007 22883233 PMC4014071 · DOI
  46. [54]Li C Chen M He X Ouyang D A mini-review on ion fluxes that regulate NLRP3 inflammasome activation Acta Biochim Biophys Sin (Shanghai) 2021 53 2 131 139 10.1093/abbs/gmaa155 33355638 · DOI
  47. [55]Kayagaki N Wong MT Stowe IB Ramani SR Gonzalez LC Akashi-Takamura S Noncanonical inflammasome activation by intracellular LPS independent of TLR4 Science 2013 341 6151 1246 1249 10.1126/science.1240248 23887873 · DOI
  48. [57]Kayagaki N Stowe IB Lee BL O'Rourke K Anderson K Warming S Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling Nature 2015 526 7575 666 671 10.1038/nature15541 26375259 · DOI · Paper page
  49. [58]Moretti J Jia B Hutchins Z Roy S Yip H Wu J Caspase-11 interaction with NLRP3 potentiates the noncanonical activation of the NLRP3 inflammasome Nat Immunol 2022 23 5 705 717 10.1038/s41590-022-01192-4 35487985 PMC9106893 · DOI
  50. [59]de Sa KSG Amaral LA Rodrigues TS Ishimoto AY de Andrade WAC de Almeida L Gasdermin-D activation promotes NLRP3 activation and host resistance to Leishmania infection Nat Commun 2023 14 1 1049 10.1038/s41467-023-36626-6 36828815 PMC9958042 · DOI
  51. [60]Zhu F Ma J Li W Liu Q Qin X Qian Y The orphan receptor Nur77 binds cytoplasmic LPS to activate the non-canonical NLRP3 inflammasome Immunity 2023 56 4 753 67 e8 10.1016/j.immuni.2023.03.003 37001519 · DOI
  52. [61]Chang M Wang Z Dong C Zhou R Chen L Huang H Ultrasound-amplified enzyodynamic tumor therapy by perovskite nanoenzyme-enabled cell pyroptosis and cascade catalysis Adv Mater 2023 35 7 e2208817 10.1002/adma.202208817 36529686 · DOI
  53. [62]Sun L Li X Luo Z Li M Liu H Zhu Z Purinergic receptor P2X7 contributes to abdominal aortic aneurysm development via modulating macrophage pyroptosis and inflammation Transl Res 2023 10.1016/j.trsl.2023.03.002 36967061 · DOI · Paper page
  54. [63]Nakagawa K Gonzalez-Roca E Souto A Kawai T Umebayashi H Campistol JM Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes Ann Rheum Dis 2015 74 3 603 610 10.1136/annrheumdis-2013-204361 24326009 · DOI
  55. [64]Bertoni A Carta S Baldovini C Penco F Balza E Borghini S A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: therapeutic efficacy of proton pump inhibitors J Allergy Clin Immunol 2020 145 1 368 78 e13 10.1016/j.jaci.2019.05.034 31194989 · DOI
  56. [65]Ito S Hara Y Kubota T CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction Arthritis Res Ther 2014 16 1 R52 10.1186/ar4483 24517500 PMC4060228 · DOI
  57. [66]Mortimer L Moreau F MacDonald JA Chadee K NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations Nat Immunol 2016 17 10 1176 1186 10.1038/ni.3538 27548431 · DOI
  58. [67]Lachmann HJ Lowe P Felix SD Rordorf C Leslie K Madhoo S In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes J Exp Med 2009 206 5 1029 1036 10.1084/jem.20082481 19364880 PMC2715040 · DOI
  59. [68]Stackowicz J Gaudenzio N Serhan N Conde E Godon O Marichal T Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome J Exp Med 2021 10.1084/jem.20201466 34477811 PMC8421266 · DOI
  60. [69]Romano M Arici ZS Piskin D Alehashemi S Aletaha D Barron KS The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist Ann Rheum Dis 2022 81 7 907 921 10.1136/annrheumdis-2021-221801 35623638 · DOI
  61. [70]Neven B Marvillet I Terrada C Ferster A Boddaert N Couloignier V Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome Arthritis Rheum 2010 62 1 258 267 10.1002/art.25057 20039428 · DOI
  62. [71]Theodoropoulou K Spel L Zaffalon L Delacretaz M Hofer M Martinon F NLRP3 leucine-rich repeats control induced and spontaneous inflammasome activation in cryopyrin-associated periodic syndrome J Allergy Clin Immunol 2023 151 1 222 32 e9 10.1016/j.jaci.2022.08.019 36075321 · DOI
  63. [72]Ma JH Lee E Yoon SH Min H Oh JH Hwang I Therapeutic effect of NLRP3 inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model EBioMedicine 2022 82 104184 10.1016/j.ebiom.2022.104184 35870427 PMC9307460 · DOI
  64. [73]Chae JJ Cho YH Lee GS Cheng J Liu PP Feigenbaum L Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice Immunity 2011 34 5 755 768 10.1016/j.immuni.2011.02.020 21600797 PMC3129608 · DOI
  65. [74]Stoler I Freytag J Orak B Unterwalder N Henning S Heim K Gene-dose effect of MEFV gain-of-function mutations determines ex vivo neutrophil activation in familial Mediterranean fever Front Immunol 2020 11 716 10.3389/fimmu.2020.00716 32655537 PMC7325897 · DOI
  66. [75]Jorch SK McNally A Berger P Wolf J Kaiser K ChetruscaCovash A Complex regulation of alarmins S100A8/A9 and secretion via gasdermin D pores exacerbates autoinflammation in familial Mediterranean fever J Allergy Clin Immunol 2023 10.1016/j.jaci.2023.01.037 36822481 · DOI
  67. [76]Omenetti A Carta S Delfino L Martini A Gattorno M Rubartelli A Increased NLRP3-dependent interleukin 1beta secretion in patients with familial Mediterranean fever: correlation with MEFV genotype Ann Rheum Dis 2014 73 2 462 469 10.1136/annrheumdis-2012-202774 23505242 · DOI
  68. [77]Mortensen SB Hansen AE Mogensen TH Jakobsen MA Beck HC Harvald EB Pyrin inflammasome activation abrogates interleukin-1 receptor antagonist, suggesting a new mechanism underlying familial Mediterranean fever pathogenesis Arthritis Rheumatol 2021 73 11 2116 2126 10.1002/art.41770 33913256 · DOI
  69. [78]Kovacs GG Concepts and classification of neurodegenerative diseases Handb Clin Neurol 2017 145 301 307 10.1016/B978-0-12-802395-2.00021-3 28987178 · DOI
  70. [79]Panicker N Kam TI Wang H Neifert S Chou SC Kumar M Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease Neuron 2022 110 15 2422 37 e9 10.1016/j.neuron.2022.05.009 35654037 PMC9357148 · DOI
  71. [80]Jung ES Suh K Han J Kim H Kang HS Choi WS Amyloid-beta activates NLRP3 inflammasomes by affecting microglial immunometabolism through the Syk-AMPK pathway Aging Cell 2022 21 5 e13623 10.1111/acel.13623 35474599 PMC9124305 · DOI
  72. [81]Pradhan LK Sahoo PK Chauhan S Das SK Recent advances towards diagnosis and therapeutic fingerprinting for Alzheimer's disease J Mol Neurosci 2022 72 6 1143 1165 10.1007/s12031-022-02009-7 35553375 · DOI
  73. [83]Achudhan D Liu SC Lin YY Huang CC Tsai CH Ko CY Antcin K inhibits TNF-alpha, IL-1beta and IL-8 expression in synovial fibroblasts and ameliorates cartilage degradation: implications for the treatment of rheumatoid arthritis Front Immunol 2021 12 790925 10.3389/fimmu.2021.790925 34975889 PMC8714747 · DOI
  74. [84]Goldmann T Tay TL Prinz M Love and death: microglia, NLRP3 and the Alzheimer's brain Cell Res 2013 23 5 595 596 10.1038/cr.2013.24 23399597 PMC3641594 · DOI
  75. [85]Zhang Y Dong Z Song W NLRP3 inflammasome as a novel therapeutic target for Alzheimer's disease Signal Transduct Target Ther 2020 5 1 37 10.1038/s41392-020-0145-7 32296063 PMC7109024 · DOI
  76. [87]Fang Y Yao L Li C Wang J Wang J Chen S The blockage of the Nogo/NgR signal pathway in microglia alleviates the formation of Abeta plaques and tau phosphorylation in APP/PS1 transgenic mice J Neuroinflamm 2016 13 1 56 10.1186/s12974-016-0522-x PMC4776389 26939570 · DOI
  77. [89]Domellof ME Elgh E Forsgren L The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease Mov Disord 2011 26 12 2183 2189 10.1002/mds.23814 21661051 · DOI
  78. [90]Lee AJ Kim C Park S Joo J Choi B Yang D Characterization of altered molecular mechanisms in Parkinson's disease through cell type-resolved multiomics analyses Sci Adv 2023 9 15 eaob2467 10.1126/sciadv.abo2467 PMC10104466 37058563 · DOI
  79. [91]Zheng Z Lv Y Rong S Sun T Chen L Physical frailty, genetic predisposition, and incident Parkinson disease JAMA Neurol 2023 10.1001/jamaneurol.2023.0183 36912851 PMC10012040 · DOI
  80. [92]Bellomo G Paciotti S Concha-Marambio L Rizzo D Wojdaƚa AL Chiasserini D Cerebrospinal fluid lipoproteins inhibit alpha-synuclein aggregation by interacting with oligomeric species in seed amplification assays Mol Neurodegener 2023 18 1 20 10.1186/s13024-023-00613-8 37005644 PMC10068178 · DOI
  81. [93]Chen X Feng Y Quinn RJ Pountney DL Richardson DR Mellick GD Potassium channels in Parkinson's disease: potential roles in its pathogenesis and innovative molecular targets for treatment Pharmacol Rev 2023 10.1124/pharmrev.122.000743 36918260 · DOI
  82. [94]Liu Y Liu T Zhou Y Li W Wang M Song N Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease Acta Pharm Sin B 2023 13 2 662 677 10.1016/j.apsb.2022.07.021 36873178 PMC9978855 · DOI
  83. [95]Fan Z Pan YT Zhang ZY Yang H Yu SY Zheng Y Systemic activation of NLRP3 inflammasome and plasma alpha-synuclein levels are correlated with motor severity and progression in Parkinson's disease J Neuroinflamm 2020 17 1 11 10.1186/s12974-019-1670-6 PMC6950934 31915018 · DOI · Paper page
  84. [97]Xie W Chung KK Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease J Neurochem 2012 122 2 404 414 10.1111/j.1471-4159.2012.07769.x 22537068 · DOI
  85. [98]Gordon R Albornoz EA Christie DC Langley MR Kumar V Mantovani S Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice Sci Transl Med. 2018 10.1126/scitranslmed.aah4066 30381407 PMC6483075 · DOI · Paper page
  86. [99]Lee E Hwang I Park S Hong S Hwang B Cho Y MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration Cell Death Differ 2019 26 2 213 228 10.1038/s41418-018-0124-5 29786072 PMC6329843 · DOI · Paper page
  87. [100]Cheng J Liao Y Dong Y Hu H Yang N Kong X Microglial autophagy defect causes Parkinson disease-like symptoms by accelerating inflammasome activation in mice Autophagy 2020 16 12 2193 2205 10.1080/15548627.2020.1719723 32003282 PMC7751565 · DOI · Paper page
  88. [101]Qin Y Qiu J Wang P Liu J Zhao Y Jiang F Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson's disease Brain Behav Immun 2021 91 324 338 10.1016/j.bbi.2020.10.010 33039664 · DOI
  89. [102]Ma X Hao J Wu J Li Y Cai X Zheng Y Prussian blue nanozyme as a pyroptosis inhibitor alleviates neurodegeneration Adv Mater 2022 34 15 e2106723 10.1002/adma.202106723 35143076 · DOI
  90. [103]Pike AF Longhena F Faustini G van Eik JM Gombert I Herrebout MAC Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease J Neuroinflamm 2022 19 1 50 10.1186/s12974-022-02410-4 PMC8848816 35172843 · DOI
  91. [104]Ahmed S Kwatra M Ranjan Panda S Murty USN Naidu VGM Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease Brain Behav Immun 2021 91 142 158 10.1016/j.bbi.2020.09.017 32971182 · DOI
  92. [105]Keller CG Shin Y Monteys AM Renaud N Beibel M Teider N An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion Nat Commun 2022 13 1 1150 10.1038/s41467-022-28653-6 35241644 PMC8894458 · DOI
  93. [106]Barake F Soza A Gonzalez A Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities Curr Opin Neurol 2020 33 3 381 390 10.1097/WCO.0000000000000812 32304438 · DOI
  94. [107]Ren Z Liang W Sheng J Xun C Xu T Cao R 2019 Gal-3 is a potential biomarker for spinal cord injury and Gal-3 deficiency attenuates neuroinflammation through ROS/TXNIP/NLRP3 signaling pathway Biosci Rep. 10.1042/BSR20192368 PMC6923351 31763668 · DOI
  95. [108]Siew JJ Chen HM Chen HY Chen HL Chen CM Soong BW Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease Nat Commun 2019 10 1 3473 10.1038/s41467-019-11441-0 31375685 PMC6677843 · DOI
  96. [109]Paldino E D'Angelo V Sancesario G Fusco FR Pyroptotic cell death in the R6/2 mouse model of Huntington's disease: new insight on the inflammasome Cell Death Discov. 2020 6 69 10.1038/s41420-020-00293-z 32821438 PMC7395807 · DOI
  97. [110]Chen KP Hua KF Tsai FT Lin TY Cheng CY Yang DI A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease J Neuroinflamm 2022 19 1 56 10.1186/s12974-022-02419-9 PMC8882273 35219323 · DOI
  98. [111]Paldino E D'Angelo V Laurenti D Angeloni C Sancesario G Fusco FR Modulation of inflammasome and pyroptosis by olaparib, a PARP-1 inhibitor, in the R6/2 mouse model of Huntington's disease Cells 2020 10.3390/cells9102286 33066292 PMC7602058 · DOI
  99. [112]Schunk SJ Kleber ME Marz W Pang S Zewinger S Triem S Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality Eur Heart J 2021 42 18 1742 1756 10.1093/eurheartj/ehab107 33748830 PMC8244638 · DOI
  100. [113]Orecchioni M Kobiyama K Winkels H Ghosheh Y McArdle S Mikulski Z Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production Science 2022 375 6577 214 221 10.1126/science.abg3067 35025664 PMC9744443 · DOI
  101. [114]Bjorkegren JLM Lusis AJ Atherosclerosis: recent developments Cell 2022 185 10 1630 1645 10.1016/j.cell.2022.04.004 35504280 PMC9119695 · DOI
  102. [115]Gu P Hui X Zheng Q Gao Y Jin L Jiang W Mitochondrial uncoupling protein 1 antagonizes atherosclerosis by blocking NLRP3 inflammasome-dependent interleukin-1beta production Sci Adv 2021 7 50 eabl4024 10.1126/sciadv.abl4024 34878840 PMC8654294 · DOI
  103. [117]Wang Y Ji N Gong X Ni S Xu L Zhang H Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome Endocrine 2020 70 1 65 70 10.1007/s12020-020-02389-z 32607763 · DOI
  104. [118]Wu X Zhang H Qi W Zhang Y Li J Li Z Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis Cell Death Dis 2018 9 2 171 10.1038/s41419-017-0257-3 29416034 PMC5833729 · DOI
  105. [119]Ziaeian B Fonarow GC Epidemiology and aetiology of heart failure Nat Rev Cardiol 2016 13 6 368 378 10.1038/nrcardio.2016.25 26935038 PMC4868779 · DOI
  106. [120]Wang S Zhang J Wang Y Jiang X Guo M Yang Z NLRP3 inflammasome as a novel therapeutic target for heart failure Anatol J Cardiol 2022 26 1 15 22 10.5152/AnatolJCardiol.2021.580 35191381 PMC8878950 · DOI
  107. [121]Zeng C Duan F Hu J Luo B Huang B Lou X NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy Redox Biol 2020 34 101523 10.1016/j.redox.2020.101523 32273259 PMC7327979 · DOI
  108. [122]Byrne NJ Matsumura N Maayah ZH Ferdaoussi M Takahara S Darwesh AM Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure Circ Heart Fail 2020 13 1 e006277 10.1161/CIRCHEARTFAILURE.119.006277 31957470 · DOI
  109. [123]Karim MA Singal AG Kum HC Lee YT Park S Rich NE Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States Clin Gastroenterol Hepatol 2022 10.1016/j.cgh.2022.03.010 35307595 PMC9481743 · DOI
  110. [124]Sundaram V Jalan R Shah P Singal AK Patel AA Wu T Acute on chronic liver failure from nonalcoholic fatty liver disease: a growing and aging cohort with rising mortality Hepatology 2021 73 5 1932 1944 10.1002/hep.31566 32961608 · DOI
  111. [126]Yang SJ Lim Y Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation Metabolism 2014 63 5 693 701 10.1016/j.metabol.2014.02.003 24629563 · DOI
  112. [127]Calcagno DM Chu A Gaul S Taghdiri N Toomu A Leszczynska A NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH Hepatology 2022 76 3 727 741 10.1002/hep.32320 34997987 PMC10176600 · DOI
  113. [128]Lin Z Xie X Gu M Chen Q Lu G Jia X microRNA-144/451 decreases dendritic cell bioactivity via targeting interferon-regulatory factor 5 to limit DSS-induced colitis Front Immunol 2022 13 928593 10.3389/fimmu.2022.928593 35967345 PMC9372465 · DOI
  114. [129]Hsieh YT Chou YC Kuo PY Tsai HW Yen YT Shiau AL Down-regulated miR-146a expression with increased neutrophil extracellular traps and apoptosis formation in autoimmune-mediated diffuse alveolar hemorrhage J Biomed Sci 2022 29 1 62 10.1186/s12929-022-00849-4 36028828 PMC9413930 · DOI
  115. [130]Cheung O Puri P Eicken C Contos MJ Mirshahi F Maher JW Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression Hepatology 2008 48 6 1810 1820 10.1002/hep.22569 19030170 PMC2717729 · DOI
  116. [132]Jimenez Calvente C Del Pilar H Tameda M Johnson CD Feldstein AE MicroRNA 223 3p negatively regulates the NLRP3 inflammasome in acute and chronic liver injury Mol Ther 2020 28 2 653 663 10.1016/j.ymthe.2019.09.013 31585800 PMC7000998 · DOI
  117. [133]Gines P Krag A Abraldes JG Sola E Fabrellas N Kamath PS Liver cirrhosis Lancet 2021 398 10308 1359 1376 10.1016/S0140-6736(21)01374-X 34543610 · DOI · Paper page
  118. [134]Ma X Zheng X Pan L Zhang X NLRP3 inflammasome activation in liver cirrhotic patients Biochem Biophys Res Commun 2018 505 1 40 44 10.1016/j.bbrc.2018.09.055 30236988 · DOI
  119. [135]Chen P Zhou YK Han CS Chen LJ Wang YM Zhuang ZM Stem cells from human exfoliated deciduous teeth alleviate liver cirrhosis via inhibition of gasdermin D-executed hepatocyte pyroptosis Front Immunol 2022 13 860225 10.3389/fimmu.2022.860225 35634294 PMC9133376 · DOI · Paper page
  120. [136]Barnett R Liver cirrhosis Lancet 2018 392 10144 275 10.1016/S0140-6736(18)31659-3 30064644 · DOI
  121. [138]Yaping Z Ying W Luqin D Ning T Xuemei A Xixian Y Mechanism of interleukin-1beta-induced proliferation in rat hepatic stellate cells from different levels of signal transduction APMIS 2014 122 5 392 398 10.1111/apm.12155 23992404 · DOI
  122. [139]Zhu Z Hu R Li J Xing X Chen J Zhou Q Alpinetin exerts anti-inflammatory, anti-oxidative and anti-angiogenic effects through activating the Nrf2 pathway and inhibiting NLRP3 pathway in carbon tetrachloride-induced liver fibrosis Int Immunopharmacol 2021 96 107660 10.1016/j.intimp.2021.107660 33862553 · DOI
  123. [140]Kim HY Choi YJ Kim SK Kim H Jun DW Yoon K Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome Commun Biol 2021 4 1 824 10.1038/s42003-021-02345-1 34193972 PMC8245406 · DOI
  124. [141]Gaul S Leszczynska A Alegre F Kaufmann B Johnson CD Adams LA Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis J Hepatol 2021 74 1 156 167 10.1016/j.jhep.2020.07.041 32763266 PMC7749849 · DOI
  125. [142]Wree A Eguchi A McGeough MD Pena CA Johnson CD Canbay A NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice Hepatology 2014 59 3 898 910 10.1002/hep.26592 23813842 PMC4008151 · DOI · Paper page
  126. [143]Liu B Zhou Z Jin Y Lu J Feng D Peng R Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma J Immunother Cancer 2022 10.1136/jitc-2021-003069 34996812 PMC8744134 · DOI
  127. [144]Bauer C Duewell P Mayer C Lehr HA Fitzgerald KA Dauer M Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome Gut 2010 59 9 1192 1199 10.1136/gut.2009.197822 20442201 · DOI
  128. [145]Zaki MH Boyd KL Vogel P Kastan MB Lamkanfi M Kanneganti TD The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis Immunity 2010 32 3 379 391 10.1016/j.immuni.2010.03.003 20303296 PMC2982187 · DOI · Paper page
  129. [146]Liu L Dong Y Ye M Jin S Yang J Joosse ME The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans J Crohns Colitis 2017 11 6 737 750 27993998 PMC5881697
  130. [147]Villani AC Lemire M Fortin G Louis E Silverberg MS Collette C Common variants in the NLRP3 region contribute to Crohn's disease susceptibility Nat Genet 2009 41 1 71 76 10.1038/ng.285 19098911 PMC2728932 · DOI
  131. [148]Mao L Kitani A Similuk M Oler AJ Albenberg L Kelsen J Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease J Clin Invest 2018 128 5 1793 1806 10.1172/JCI98642 29408806 PMC5919822 · DOI
  132. [149]Wang K Lv Q Miao YM Qiao SM Dai Y Wei ZF Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway Biochem Pharmacol 2018 155 494 509 10.1016/j.bcp.2018.07.039 30071202 · DOI
  133. [150]Tian M Ma P Zhang Y Mi Y Fan D Ginsenoside Rk3 alleviated DSS-induced ulcerative colitis by protecting colon barrier and inhibiting NLRP3 inflammasome pathway Int Immunopharmacol 2020 85 106645 10.1016/j.intimp.2020.106645 32521491 · DOI
  134. [151]Itani S Watanabe T Nadatani Y Sugimura N Shimada S Takeda S NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis Sci Rep 2016 6 39075 10.1038/srep39075 27966619 PMC5155456 · DOI
  135. [152]Yao X Zhang C Xing Y Xue G Zhang Q Pan F Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis Nat Commun 2017 8 1 1896 10.1038/s41467-017-01917-2 29196621 PMC5711854 · DOI
  136. [153]Gong Z He Y Zhou M Xin H Pan M Fiaz M Ultrasound imaging tracking of mesenchymal stem cells intracellularly labeled with biosynthetic gas vesicles for treatment of rheumatoid arthritis Theranostics 2022 12 5 2370 2382 10.7150/thno.66905 35265215 PMC8899585 · DOI
  137. [154]Yokota K Sato K Miyazaki T Aizaki Y Tanaka S Sekikawa M Characterization and function of tumor necrosis factor and interleukin-6-induced osteoclasts in rheumatoid arthritis Arthritis Rheumatol 2021 73 7 1145 1154 10.1002/art.41666 33512089 PMC8361923 · DOI
  138. [155]Cheng L Liang X Qian L Luo C Li D NLRP3 gene polymorphisms and expression in rheumatoid arthritis Exp Ther Med 2021 22 4 1110 10.3892/etm.2021.10544 34504564 PMC8383757 · DOI
  139. [156]Guo C Fu R Wang S Huang Y Li X Zhou M NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis Clin Exp Immunol 2018 194 2 231 243 10.1111/cei.13167 30277570 PMC6194337 · DOI
  140. [157]Dong X Zheng Z Lin P Fu X Li F Jiang J ACPAs promote IL-1beta production in rheumatoid arthritis by activating the NLRP3 inflammasome Cell Mol Immunol 2020 17 3 261 271 10.1038/s41423-019-0201-9 30911117 PMC7052171 · DOI
  141. [158]Jager E Murthy S Schmidt C Hahn M Strobel S Peters A Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis Nat Commun 2020 11 1 4243 10.1038/s41467-020-17749-6 32843625 PMC7447633 · DOI
  142. [159]Renaudin F Orliaguet L Castelli F Fenaille F Prignon A Alzaid F Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1beta activation on macrophages Ann Rheum Dis 2020 79 11 1506 1514 10.1136/annrheumdis-2020-217342 32699039 · DOI
  143. [161]Terkeltaub R Sundy JS Schumacher HR Murphy F Bookbinder S Biedermann S The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study Ann Rheum Dis 2009 68 10 1613 1617 10.1136/ard.2009.108936 19635719 PMC2732898 · DOI
  144. [162]Kingsbury SR Conaghan PG McDermott MF The role of the NLRP3 inflammasome in gout J Inflamm Res 2011 4 39 49 22096368 PMC3218743
  145. [164]Lachmann HJ Kone-Paut I Kuemmerle-Deschner JB Leslie KS Hachulla E Quartier P Use of canakinumab in the cryopyrin-associated periodic syndrome N Engl J Med 2009 360 23 2416 2425 10.1056/NEJMoa0810787 19494217 · DOI · Paper page
  146. [165]Kuemmerle-Deschner JB Hachulla E Cartwright R Hawkins PN Tran TA Bader-Meunier B Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes Ann Rheum Dis 2011 70 12 2095 2102 10.1136/ard.2011.152728 21859692 · DOI
  147. [166]van Hout GP Bosch L Ellenbroek GH de Haan JJ van Solinge WW Cooper MA The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction Eur Heart J 2017 38 11 828 836 27432019
  148. [167]Ren H Kong Y Liu Z Zang D Yang X Wood K Selective NLRP3 (pyrin domain-containing protein 3) inflammasome inhibitor reduces brain injury after intracerebral hemorrhage Stroke 2018 49 1 184 192 10.1161/STROKEAHA.117.018904 29212744 PMC5753818 · DOI
  149. [168]Chen L Huang CF Li YC Deng WW Mao L Wu L Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma Cell Mol Life Sci 2018 75 11 2045 2058 10.1007/s00018-017-2720-9 29184980 PMC11105265 · DOI
  150. [169]Wu M Yang Z Zhang C Shi Y Han W Song S Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy Metabolism 2021 118 154748 10.1016/j.metabol.2021.154748 33675822 · DOI
  151. [170]Coll RC Hill JR Day CJ Zamoshnikova A Boucher D Massey NL MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition Nat Chem Biol 2019 15 6 556 559 10.1038/s41589-019-0277-7 31086327 · DOI
  152. [172]Tapia-Abellan A Angosto-Bazarra D Martinez-Banaclocha H de Torre-Minguela C Ceron-Carrasco JP Perez-Sanchez H MCC950 closes the active conformation of NLRP3 to an inactive state Nat Chem Biol 2019 15 6 560 564 10.1038/s41589-019-0278-6 31086329 PMC7116292 · DOI
  153. [174]Shippy DC Wilhelm C Viharkumar PA Raife TJ Ulland TK beta-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology J Neuroinflamm 2020 17 1 280 10.1186/s12974-020-01948-5 PMC7507727 32958021 · DOI
  154. [175]Luo S Yang M Han Y Zhao H Jiang N Li L beta-Hydroxybutyrate against Cisplatin-Induced acute kidney injury via inhibiting NLRP3 inflammasome and oxidative stress Int Immunopharmacol 2022 111 109101 10.1016/j.intimp.2022.109101 35940076 · DOI
  155. [176]Corcoran SE Halai R Cooper MA Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950 Pharmacol Rev 2021 73 3 968 1000 10.1124/pharmrev.120.000171 34117094 · DOI
  156. [177]Feng X Zhan F Luo D Hu J Wei G Hua F LncRNA 4344 promotes NLRP3-related neuroinflammation and cognitive impairment by targeting miR-138–5p Brain Behav Immun 2021 98 283 298 10.1016/j.bbi.2021.08.230 34455059 · DOI
  157. [178]Hu H Wang Y Ding X He Y Lu Z Wu P Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3 Mol Cancer 2018 17 1 18 10.1186/s12943-018-0761-9 29386037 PMC5793431 · DOI
  158. [179]Richards MW O'Regan L Mas-Droux C Blot JM Cheung J Hoelder S An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9 Mol Cell 2009 36 4 560 570 10.1016/j.molcel.2009.09.038 19941817 PMC2807034 · DOI
  159. [180]Kim SK Choe JY Park KY Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7 Biochem Biophys Res Commun 2019 517 2 338 345 10.1016/j.bbrc.2019.07.087 31358323 · DOI
  160. [181]Chen Y He H Lin B Chen Y Deng X Jiang W RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor Cell Mol Immunol 2021 18 6 1425 1436 10.1038/s41423-021-00683-y 33972740 PMC8166941 · DOI
  161. [182]Coll RC Schroder K Pelegrin P NLRP3 and pyroptosis blockers for treating inflammatory diseases Trends Pharmacol Sci 2022 43 8 653 668 10.1016/j.tips.2022.04.003 35513901 · DOI
  162. [183]Sharma BR Kanneganti TD NLRP3 inflammasome in cancer and metabolic diseases Nat Immunol 2021 22 5 550 559 10.1038/s41590-021-00886-5 33707781 PMC8132572 · DOI
  163. [184]Tengesdal IW Menon DR Osborne DG Neff CP Powers NE Gamboni F Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion Proc Natl Acad Sci U S A 2021 10.1073/pnas.2000915118 33649199 PMC7958415 · DOI
  164. [185]Dupaul-Chicoine J Arabzadeh A Dagenais M Douglas T Champagne C Morizot A The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity Immunity 2015 43 4 751 763 10.1016/j.immuni.2015.08.013 26384545 · DOI · Paper page

Cited by

Sorted by citations

Authors
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., Acuña-Castroviejo, D., & Yang, Y.
Affiliations
  • First Affiliated Hospital of Xi'an Jiaotong University (CN)
  • Northwest University (CN)
  • Universidad de Granada (ES)
  • Yan'an University (CN)
  • Chinese People's Liberation Army (CN)
Corresponding author
Yang, Yang
ORCID
Venue
Cellular & Molecular Biology Letters
Publisher
Springer Science and Business Media LLC
Published
2023-06-27
Volume
28
Issue
1
Pages
51-51
ISSN
  • 1425-8153 (ISSN-L)
  • 1689-1392
DOI
10.1186/s11658-023-00462-9
PMC
PMC10303833
OpenAlex
W4382239618
Cited by
492
References
21
Citations by year
2026: 211 · 2025: 191 · 2024: 83 · 2023: 7
FWCI
42.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Cellular & Molecular Biology Letters (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82200330, 82070422, 81871607)
  • Youth Science and Technology Rising Star Project of Shaanxi Province (2020KJXX-036)
  • Innovation Capability Strong Foundation Plan of Xi’an City (21YXYJ0037)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords
NLRP3 inflammasome, caspase-1, IL-1β, IL-18, innate immunity, inflammation-related diseases, arthritis, Alzheimer's disease, inflammatory bowel disease, autoimmune disease, autoinflammatory disease, inflammasome activation, inflammasome-targeted therapy
MeSH terms
NLR Proteins, NLR Family, Pyrin Domain-Containing 3 Protein, Humans, Immunity, Innate, Inflammation, Interleukin-1beta, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review